Urinary Incontinence News and Research

Latest Urinary Incontinence News and Research

Uroplasty's Urgent PC and Macroplastique presented at the International Continence Society Meeting

Uroplasty, Inc., a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment of voiding dysfunctions, today highlighted presentations, workshops and posters focused on its products at the 39th Annual Meeting of the International Continence Society Meeting (ICS), September 29 - October 3 in San Francisco.

7 Oct 2009

Strengthening the pelvic floor muscles effective for older women with urinary incontinence

Researchers at Rush University Medical Center have found that a program of pelvic floor muscle exercises, combined with pelvic health education, can be an effective way to manage urinary incontinence in elderly women.

3 Oct 2009

Urodynamix: Cross of 1,480,000 common shares effected through Canaccord Capital

Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announced that a cross of 1,480,000 common shares has been effected through Canaccord Capital Inc. at a sales price of $0.05 per common share.

30 Sep 2009

AMS’ products restore patient's pelvic health and their quality of life

American Medical Systems® (AMS), a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the results of three major clinical studies that each point to a high degree of efficacy and patient satisfaction with AMS’ minimally invasive treatment options for female stress urinary incontinence (SUI) and vaginal prolapse.

30 Sep 2009

Urodynamix closes $1.5 million non-brokered private placement for common shares

Urodynamix Technologies Ltd. (TSX VENTURE:URO) is pleased to announce that it has closed a $1.5 million non-brokered private placement for 30,000,000 common shares previously reported on September 11, 2009.

29 Sep 2009

Quintiles Transnational enter into marketing agreement with Allergan for SANCTURA XR

Quintiles Transnational Corp. and Allergan, Inc. (NYSE: AGN) today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR® (trospium chloride extended release capsules), an anticholinergic approved for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency, predominantly to primary care physicians in the United States.

28 Sep 2009

Initial clinical results for Mpathy Medical's Omnisure sling released

Mpathy Medical, a rapidly growing medical device company which has developed and brought to market a range of less invasive surgical solutions used to restore pelvic health to women, released the initial clinical results for its newest product, Omnisure™, a novel full length sling for treatment of female stress urinary incontinence (SUI) at the American Urogynecologic Society’s (AUGS) Annual Meeting.

26 Sep 2009

NHSSC awards contract to AMS to supply SUI treatment devices in UK

American Medical Systems (AMS), a leading provider of world-class devices and therapies for both male and female pelvic health, announced today that it has been included as part of a multiple-awardees contract by National Healthcare Services (NHS) Supply Chain (NHSSC) to supply three of its clinically-proven female stress urinary incontinence (SUI) treatment devices through the Normanton distribution centre, United Kingdom.

24 Sep 2009

Palmetto GBA-TrailBlazer Health cover Renessa treatment of female SUI

Novasys Medical, Inc., a developer of innovative therapies in women's health, announced today that Palmetto GBA and TrailBlazer Health Enterprises, LLC -- two large regional Medicare carriers serving over 10.2 million beneficiaries in California, Nevada, Hawaii, Texas, Oklahoma, Colorado, New Mexico and Virginia -- have agreed to cover the Renessa(R) treatment for female SUI (stress urinary incontinence) in appropriately selected patients with documented medical necessity.

24 Sep 2009

FemSoft from Rochester Medical included in the UK Drug Tariff

Rochester Medical Corporation (Nasdaq: ROCM) today announced that the Company's FemSoft(R) Insert has been approved for inclusion in Part IX of the UK Drug Tariff as a prescription product which is reimbursable.

22 Sep 2009

Workshop to educate women on urinary incontinence

UCSF and the National Association For Continence (NAFC) are holding a public workshop on October 3 to help women understand how they can control and treat incontinence.

17 Sep 2009

Boston Scientific to market Bladder Health Network's female urodynamic testing solutions in the U.S.

Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a co-marketing agreement with Bladder Health Network, a privately held company offering advanced testing solutions for urinary incontinence. Bladder Health Network offers an integrated diagnostic service that combines staffing, equipment, supplies and results analysis, helping to ensure that physicians and their patients have access to testing, interpretation and treatment options for urinary incontinence and other problems related to the urinary system.

14 Sep 2009

Urodynamix Technologies raises funds through private placement

Urodynamix Technologies Ltd. (TSX VENTURE:URO) is pleased to announce that it is raising a minimum of $1,500,000 through the issuance of 30,000,000 common shares of the Company at a price of $0.05 per common share. BC Advantage Funds has provided the Company with a lead order of $750,000.

14 Sep 2009

AMS adds a 3.5 cm Occlusive Cuff to its product line

American Medical Systems, Inc. (AMS), a trusted provider of medical solutions for restoring men’s and women’s pelvic health, announced today that it has expanded its AMS 800 male artificial urinary sphincter product line with the addition of a 3.5 cm Occlusive Cuff to restore urinary continence to a wider range of male patients.

9 Sep 2009

Regurin XL capsule for the treatment of OAB launched in UK

Regurin(R) XL (trospium chloride), a once-daily, prolonged-release capsule to treat patients with overactive bladder (OAB) has been launched in the UK. Regurin(R) XL provides rapid, significant and consistent improvements in the symptoms of OAB1 and has a reduced potential for central nervous system (CNS) side effects(2-7).

7 Sep 2009

Periurethral suspension technique results in greater continence rates after RALIP

The September issue of European Urology, the official journal of the European Association of Urology, features an article and a video in the Surgery in Motion section by Vipul R. Patel et al, showing that the periurethral suspension technique results in significantly greater continence rates at 3 months after robot-assisted laparoscopic radical prostatectomy (RALP).

4 Sep 2009

CELDA used for assessing the cerebrospinal fluid granted CE marking

LinkMed’s portfolio company Likvor has been granted CE marking for its instrument for better and safer identification and diagnosis of Normal Pressure Hydrocephalus (NPH).

4 Sep 2009

Uroplasty highlights the result of OrBIT trial of its Urgent PC System

Uroplasty, Inc. (Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results published in the September, 2009 edition of THE JOURNAL OF UROLOGY(R) from the OrBIT trial of its Urgent PC System.

3 Sep 2009

Waist-hip ratio is a better of measure of obesity in older patients

Body mass index (BMI) readings may not be the best gauge of obesity in older adults, according to new research from UCLA endocrinologists and geriatricians. Instead, they say, the ratio of waist size to hip size may be a better indicator when it comes to those over 70.

2 Sep 2009

Urodynamix Technologies announces fiscal 2009 second-quarter financials

Urodynamix Technologies Ltd. (TSX VENTURE:URO) today reported its financial results for its fiscal second quarter ended June 30, 2009. The Company reported revenues of $21,871, a 70% decrease over the same quarter of the prior year. The Company's order backlog at June 30, 2009 was $92,576 compared to nil at the end of the comparative quarter June 30, 2008.

28 Aug 2009